| 产品名称： | Mumps rubulavirus |
|---|---|
| 商品货号： | TS141600 |
| Classification： | Paramyxoviridae, Rubulavirus |
| Deposited As： | Mumps |
| Agent： | Mumps rubulavirus |
| Strain： | Enders |
| Common Name： | Mumps virus |
| Applications： | This strain was used for preparation of skin test and viral V and S complement fixation antigens. Respiratory research |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1 mL per vial |
| Storage Conditions： | -70°C or colder |
| Comments： | This strain was used for preparation of skin test and viral V and S CF antigens. It is of low virulence for human volunteers. GenBank: GU980052.1 |
| Effect on Host： | CPE, cell rounding, syncytia formation, and sloughing |
| Recommended Host： | SL-29 (ATCC® CRL-1590™) |
| Growth Conditions： | Temperature: 36°C
Recommendations for Infection: Plate cells 24-48 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.1). Adsorb 1-2 hours at 36°C in a humidified 5% CO2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium.
Incubation: 5-11 days |
| Name of Depositor： | JF Enders, Childrens Medical Center, Boston, Massachusetts |
| Source： | Pooled saliva from patients, Massachusetts |
| References： | Andrews CH. A short description of the Myxovirus group (Influenza and related viruses). Virology. 2: 176-184, 1955. PubMed: 13267985. Enders JF, et al. Immunity in mumps: I. Experiments with monkeys (Macacus mulatta). The development of complement-fixing antibody following infection and experiments on immunization by means of inactivated virus and convalescent human serum. J. Exp. Med. 81: 93-117, 1945. PubMed: 19871448. Henle G, et al. The reactivity of various human sera with mumps complement fixation antigens. J. Exp. Med. 1: 133-147, 1948. PubMed: 18871883. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Mumps rubulavirus |
|---|---|
| 商品货号： | TS141600 |
| Classification： | Paramyxoviridae, Rubulavirus |
| Deposited As： | Mumps |
| Agent： | Mumps rubulavirus |
| Strain： | Enders |
| Common Name： | Mumps virus |
| Applications： | This strain was used for preparation of skin test and viral V and S complement fixation antigens. Respiratory research |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1 mL per vial |
| Storage Conditions： | -70°C or colder |
| Comments： | This strain was used for preparation of skin test and viral V and S CF antigens. It is of low virulence for human volunteers. GenBank: GU980052.1 |
| Effect on Host： | CPE, cell rounding, syncytia formation, and sloughing |
| Recommended Host： | SL-29 (ATCC® CRL-1590™) |
| Growth Conditions： | Temperature: 36°C
Recommendations for Infection: Plate cells 24-48 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.1). Adsorb 1-2 hours at 36°C in a humidified 5% CO2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium.
Incubation: 5-11 days |
| Name of Depositor： | JF Enders, Childrens Medical Center, Boston, Massachusetts |
| Source： | Pooled saliva from patients, Massachusetts |
| References： | Andrews CH. A short description of the Myxovirus group (Influenza and related viruses). Virology. 2: 176-184, 1955. PubMed: 13267985. Enders JF, et al. Immunity in mumps: I. Experiments with monkeys (Macacus mulatta). The development of complement-fixing antibody following infection and experiments on immunization by means of inactivated virus and convalescent human serum. J. Exp. Med. 81: 93-117, 1945. PubMed: 19871448. Henle G, et al. The reactivity of various human sera with mumps complement fixation antigens. J. Exp. Med. 1: 133-147, 1948. PubMed: 18871883. |
